- Home
- MTLS vs RIGL Comparison
MTLS vs RIGL Comparison
Compare MTLS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- RIGL
- Stock Information
- Founded
- MTLS 1990
- RIGL 1996
- Country
- MTLS Belgium
- RIGL United States
- Employees
- MTLS N/A
- RIGL N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- RIGL Health Care
- Exchange
- MTLS Nasdaq
- RIGL Nasdaq
- Market Cap
- MTLS 349.7M
- RIGL 335.5M
- IPO Year
- MTLS 2014
- RIGL 2000
- Fundamental
- Price
- MTLS $5.13
- RIGL $38.85
- Analyst Decision
- MTLS
- RIGL Buy
- Analyst Count
- MTLS 0
- RIGL 5
- Target Price
- MTLS N/A
- RIGL $38.20
- AVG Volume (30 Days)
- MTLS 127.2K
- RIGL 995.6K
- Earning Date
- MTLS 10-23-2025
- RIGL 08-05-2025
- Dividend Yield
- MTLS N/A
- RIGL N/A
- EPS Growth
- MTLS N/A
- RIGL N/A
- EPS
- MTLS 0.11
- RIGL 5.43
- Revenue
- MTLS $311,850,851.00
- RIGL $267,921,000.00
- Revenue This Year
- MTLS $2.98
- RIGL $59.93
- Revenue Next Year
- MTLS $7.09
- RIGL N/A
- P/E Ratio
- MTLS $48.31
- RIGL $7.15
- Revenue Growth
- MTLS 2.98
- RIGL 105.62
- 52 Week Low
- MTLS $3.93
- RIGL $12.66
- 52 Week High
- MTLS $9.69
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- MTLS 47.90
- RIGL 68.57
- Support Level
- MTLS $5.01
- RIGL $39.00
- Resistance Level
- MTLS $5.32
- RIGL $42.08
- Average True Range (ATR)
- MTLS 0.18
- RIGL 2.32
- MACD
- MTLS 0.02
- RIGL -0.37
- Stochastic Oscillator
- MTLS 52.08
- RIGL 53.26
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.